Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2024

Open Access 04-04-2024 | Mastectomy | Original Article

Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy

Authors: Hiroko Nogi, Akiko Ogiya, Makoto Ishitobi, Chikako Yamauchi, Hiroki Mori, Ayaka Shimo, Kazutaka Narui, Naomi Nagura, Hirohito Seki, Shinsuke Sasada, Teruhisa Sakurai, Tadahiko Shien, The Collaborative Study Group of Scientific Research of The Japanese Breast Cancer Society

Published in: Breast Cancer | Issue 3/2024

Login to get access

Abstract

Background

In breast cancer patients receiving neoadjuvant chemotherapy (NAC), immediate breast reconstruction (IBR) as a breast cancer treatment option remains controversial. We assessed the impact of NAC on surgical and oncological outcomes of patients undergoing IBR.

Methods

This was a retrospective multicenter study of 4726 breast cancer cases undergoing IBR. The rate of postoperative complications and survival data were compared between IBR patients who received NAC and those who did not receive NAC. Propensity score matching analysis was performed to mitigate selection bias for survival.

Results

Of the total 4726 cases, 473 (10.0%) received NAC. Out of the cases with NAC, 96 (20.3%) experienced postoperative complications, while 744 cases (17.5%) without NAC had postoperative complications. NAC did not significant increase the risk of complications after IBR (Odds ratio, 0.96; 95%CI 0.74–1.25). At the median follow-up time of 76.5 months, 36 patients in the NAC group and 147 patients in the control group developed local recurrences. The 5-year local recurrence-free survival rate was 93.1% in the NAC group and 97.1% in the control group. (P < 0.001). After matching, there was no significant difference between the two groups.

Conclusion

IBR after NAC is a safe procedure with an acceptable postoperative complication profile.
Literature
1.
Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15–23.CrossRefPubMedPubMedCentral
2.
3.
Bonadonna G, Valagussa P, Brambilla C, Ferrari LG. Preoperative chemotherapy in operable breast cancer. Lancet. 1993;341:1485.CrossRefPubMed
4.
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216–35.CrossRefPubMed
5.
Agostinetto E, Gligorov J, Piccart M. Systemic therapy for early-stage breast cancer: learning from the past to build the future Nat Rev. Clin Oncol. 2022;19:763–74.
6.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.CrossRef
7.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59.CrossRefPubMed
8.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250–68.CrossRefPubMed
9.
Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77–90.CrossRefPubMed
10.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:74–84.CrossRefPubMed
11.
Al-Ghazal SK, Sully L, Fallowfield L, Blamey RW. The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol. 2000;26:17.CrossRefPubMed
12.
Atisha D, Alderman AK, Lowery JC, Kuhn LE, Davis J, Wikins EG. Prospective analysis of long-term psychosocial outcomes in breast reconstruction: two-year postoperative results from the Michigan breast reconstruction outcomes study. Ann Surg. 2008;247:1019–28.CrossRefPubMed
13.
Retrouvey H, Kerrebijn I, Metcalfe KA, O’Neill AC, McCready DR, Hofer SOP, et al. Psychosocial functioning in women with early breast cancer treated with breast surgery with or without immediate breast reconstruction. Ann Sur Oncol. 2019;26:2444–51.CrossRef
14.
Wu ZY, Kim HJ, Lee JW, Chung IY, Kim JS, Lee SB, et al. Long-term oncologic outcomes of immediate breast reconstruction vs conventional mastectomy alone for breast cancer in the setting of neoadjuvant chemotherapy. JAMA Surg. 2020;155:1142–50.CrossRefPubMedPubMedCentral
15.
Retrouvey H, Solaja O, Gagliardi AR, Webster F, Zhong T. Barriers of access to breast reconstruction: a systematic review. Plast Reconstr Surg. 2019;143:465e–76e.CrossRefPubMed
16.
Yamakado R, Ishitobi M, Kondo N, Yamauchi C, Sasada S, Nogi H, et al. Physicians’ perception about the impact of breast reconstruction on patient prognosis: a survey in Japan. Breast Cancer. 2023;30:302–8.CrossRefPubMed
17.
Mitchem J, Herrmann D, Margenthaler JA, Aft RL. Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy. Am J Surg. 2008;196:519–22.CrossRefPubMed
18.
Dolen UC, Schmidt AC, Um GT, Sharma K, Naugton M, Zoberi I, et al. Impact of neoadjuvant and adjuvant chemotherapy on immediate tissue expander breast reconstruction. Ann Surg Oncol. 2016;23:2357–66.CrossRefPubMed
19.
Eriksson M, Anveden L, Celebioglu F, Dahlberg K, Meldahl I, Lagergren J, et al. Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort. Breast Cancer Res Treat. 2013;142:591–601.CrossRefPubMed
20.
Cordeiro PG, Albornoz CR, McCormick B, Hu Q, Van Zee K. The impact of postmastectomy radiotherapy on two-stage implant breast reconstruction: an analysis of long-term surgical outcomes, aesthetic results, and satisfaction over 13 years. Plast Reconstr Surg. 2014;134:588–95.CrossRefPubMed
21.
Varghese J, Gohari SS, Rizki H, et al. A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction. Breast. 2021;55:55–62.CrossRefPubMed
22.
Lorentzen T, Heidemann LN, Möller S, Bille C. Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48:44–52.CrossRefPubMed
23.
Donker M, Hage JJ, Woerdeman LA, Rutgers EJ, Sonke GS, Peeters MJ. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer. Eur J Surg Oncol. 2012;38:25–30.CrossRefPubMed
24.
Abt NB, Flores JM, Baltodano PA, Sarhane KA, Abreu FM, Cooney CM, et al. Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg. 2014;149:1068–76.CrossRefPubMedPubMedCentral
25.
Teotia SS, Venutolo C, Haddock NT. Outcomes in patients receiving neoadjuvant chemotherapy undergoing immediate breast reconstruction: effect of timing, postoperative complications, and delay to radiation therapy. Plast Reconstr Surg. 2019;144:732e-e742.CrossRefPubMed
26.
Riba J, de Romani SE, Masia J. Neoadjuvant chemotherapy for breast cancer treatment and the evidence-based interaction with immediate autologous and implant-based breast reconstruction. Clin Plast Surg. 2018;45:25–31.CrossRefPubMed
27.
Ryu JM, Park S, Paik HJ, Nam SJ, Kim SW, Lee SK, et al. Oncologic safety of immediate breast reconstruction in breast cancer patients who underwent neoadjuvant chemotherapy: short-term outcomes of a matched case-control study. Clin Breast Cancer. 2017;17:204–10.CrossRefPubMed
28.
Wengler CA, Valente SA, Al-Hilli Z, Woody NM, Muntean JH, Abraham J, et al. Determinants of short and long term outcomes in patients undergoing immediate breast reconstruction following neoadjuvant chemotherapy. J Surg Oncol. 2017;116:797–802.CrossRefPubMed
29.
Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, et al. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:4–8.CrossRefPubMed
30.
31.
Haffty BG, McCall LM, Ballman KV, McLaughlin S, Jagsi R, Ollila DW, et al. Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys. 2016;94:493–502.CrossRefPubMed
32.
Hoffman KE, Mittendorf EA, Buchholz TA. Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol. 2012;13:e270–6.CrossRefPubMed
Metadata
Title
Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomy
Authors
Hiroko Nogi
Akiko Ogiya
Makoto Ishitobi
Chikako Yamauchi
Hiroki Mori
Ayaka Shimo
Kazutaka Narui
Naomi Nagura
Hirohito Seki
Shinsuke Sasada
Teruhisa Sakurai
Tadahiko Shien
The Collaborative Study Group of Scientific Research of The Japanese Breast Cancer Society
Publication date
04-04-2024
Publisher
Springer Nature Singapore
Published in
Breast Cancer / Issue 3/2024
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-024-01570-w

Other articles of this Issue 3/2024

Breast Cancer 3/2024 Go to the issue

Original Article

Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX® test data: a retrospective multicenter study in Japan

Original Article

Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010–2020

Original Article

SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor β

Original Article

Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer

Original Article

Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB

Original Article

The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits